ClinicalTrials.Veeva

Menu
T

Total Skin and Beauty Dermatology Center | Birmingham, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
CTP-543
BMS-986165
Deucravacitinib
BOTOX
TAK-279
HTU-520
Upadacitinib
IDP-110
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 18 total trials
Recently updated

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Enrolling
Masseter Muscle Prominence
Drug: Placebo
Drug: BOTOX

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a po...

Active, not recruiting
Psoriatic Plaque
Drug: KBL697
Locations recently updated

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Enrolling
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

Trial sponsors

AbbVie logo
Bristol-Myers Squibb (BMS) logo
Concert Pharmaceuticals logo
Astellas logo
D
E
Genentech logo
H
Janssen (J&J Innovative Medicine) logo
K

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems